For years now, interest has been growing regarding the subject of using lasers to treat periodontal disease. Since its birth over 10 years ago, Millennium Dental Technologies has been at the forefront of encouraging doctors to consider lasers in the treatment of this disease. Here is the latest press release from them:
FOR IMMEDIATE RELEASE
LANAP® PROTOCOL SAVES TEETH OVER THE LONG TERM
10-Year Peer-Reviewed Retrospective Comparative LANAP® Study by Lloyd V. Tilt, DDS, MS was published in the 2012 March/April General Dentistry
CERRITOS, Calif. (June 13, 2012) – Millennium Dental Technologies announces more peer-reviewed results of the LANAP® protocol will be presented by periodontist Lloyd V. Tilt, DDS, MS, on Friday June 22nd, 2012 at the Academy of General Dentistry (AGD) Annual session in Philadelphia, PA. The study, published in the 2012 March/April issue of the AGD- refereed journal, General Dentistry, supports the use of the FDA-cleared LANAP protocol as an effective long-term gum disease treatment. The published study documents a 10-year retrospective on the LANAP protocol in private practice, showing the effectiveness of the LANAP protocol as measured by tooth loss, a key success metric.
“Dr. Tilt’s thorough research adds to the growing arsenal of peer-reviewed published evidence that supports the clinical results of the LANAP protocol,” says Robert H. Gregg II, DDS, president and chairman of the board at MDT. “LANAP clinicians are able to consistently reproduce preferred clinical healing outcomes – including regeneration of periodontal tissues, and regrowth of bone. Dr. Tilt’s 10-year retrospective underscores that these cases are not isolated results in the fight against gum disease, also called periodontitis. The LANAP protocol achieves consistent, predictable, regenerative outcomes and tooth retention over time.”
“This data highlights the LANAP protocol as a treatment that contributes to the long-term survival of natural dentition, and helps to avoid implant procedures,” reports Delwin K. McCarthy, DDS, chief information officer at Millennium Dental Technologies.
Dr. Tilt’s study follows 107 patients’ treatment over the course of ten years – 68% of whom were suffering from severe case IV periodontitis, measuring tooth survival as the benchmark. The retrospective study compares Tilt’s research to three other tooth survival studies of conventional periodontitis surgery. The ultimate goal of any periodontal treatment is to keep teeth in good health, comfort and function. Dr. Tilt’s research shows the LANAP protocol was at least or more effective than other treatment modalities in retaining teeth in patients with periodontal disease.
“As part of a comprehensive treatment plan, the LANAP® protocol yields consistent, predictable results, and is a preferred method of treating periodontitis,” concludes Dr. Tilt.
The full report of Dr. Tilt’s research is featured in the 2012 March/April issue of General Dentistry. An educational webinar is available at:http://tinyurl.com/ToothSurvival.
ABOUT MILLENNIUM DENTAL TECHNOLOGIES, INC. Headquartered in Cerritos, Calif., Millennium Dental Technologies, Inc. is the developer of the LANAP® protocol for the treatment of gum disease and the manufacturer of the PerioLase® MVP-7™ digital dental laser. By providing a simple and comfortable experience with unique bone-building clinical results, MDT’s FDA-cleared LANAP protocol removes the fear from gum disease treatment, offering a vastly less painful and less invasive regenerative treatment alternative to conventional scalpel/suture flap surgery; its PerioLase® MVP-7™ is a 6-watt free-running variable pulsed Nd:YAG dental laser featuring digital technology and 7 pulse durations—the most available on the market—giving it the power and versatility to perform a wide range of soft- and hard-tissue laser procedures. Established in 1990, the company’s founding clinicians, Robert H. Gregg, II, D.D.S. and Delwin K. McCarthy, D.D.S., continue to operate the company with a shared vision and purpose: To create better clinical outcomes in periodontal disease patients—and to remain true to the guiding principle—“It’s all about the patient.” For more information, visit www.LANAP.com.